Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

35
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
35
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

43
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
43
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

34
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
34
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

31
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
31
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

36
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
36
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

446
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
446

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacokinetics and pharmacodynamics of a long-acting monoclonal antibody against malaria in African adults.

The Journal of clinical investigation·2026
Same author

Duplication of superoxide dismutase and a mutation in aquaglyceroporin mediates the sensitivity of <i>Plasmodium falciparum</i> to cryptosporin, a natural product derived from <i>Acaromyces ingoldii</i>.

bioRxiv : the preprint server for biology·2026
Same author

Discovery of Novel Ionizable Lipids for Lipid Nanoparticles: Lipophilicity as a Predictor of Squaramide Head Group Lipid Clearance.

Small science·2026
Same author

Correlation Between Renal Biomarkers, Glomerular Filtration Rate, and Meropenem Clearance in Pediatric Septic Shock.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG·2026
Same author

Letter Reply to "Mind the Postpartum Trough: Closing the Clofazimine Exposure Gap After Delivery in Rifampicin-Resistant Tuberculosis".

The Journal of infectious diseases·2026
Same author

VRC01 with antiretroviral initiation in infants is well tolerated, and higher concentrations associate with greater HIV-1 DNA declines.

Science translational medicine·2026

Related Experiment Video

Updated: Oct 17, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.7K

Optimizing Dolutegravir Initiation in Neonates Using Population Pharmacokinetic Modeling and Simulation.

Joseph Piscitelli1, Mina Nikanjam1, Brookie M Best1

  • 1Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA.

Journal of Acquired Immune Deficiency Syndromes (1999)
|October 11, 2021
PubMed
Summary

Newborn dosing of dolutegravir (DTG) requires careful consideration of maternal DTG exposure. Specific neonatal dosing strategies are proposed to ensure safe and effective DTG use in infants.

More Related Videos

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.0K
MEDUSA for Identifying Death Regulatory Genes in Chemo-genetic Profiling Data
07:17

MEDUSA for Identifying Death Regulatory Genes in Chemo-genetic Profiling Data

Published on: February 7, 2025

681

Related Experiment Videos

Last Updated: Oct 17, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.7K
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.0K
MEDUSA for Identifying Death Regulatory Genes in Chemo-genetic Profiling Data
07:17

MEDUSA for Identifying Death Regulatory Genes in Chemo-genetic Profiling Data

Published on: February 7, 2025

681

Area of Science:

  • Pharmacokinetics and pharmacodynamics in neonatal populations.
  • Antiretroviral therapy in infants and pregnant women.
  • Mathematical modeling and simulation in drug development.

Background:

  • Limited data exists on dolutegravir (DTG) pharmacokinetics and safety in neonates during the first four weeks of life.
  • This knowledge gap hinders the safe and effective use of DTG in newborn populations.

Purpose of the Study:

  • To assess neonatal dolutegravir (DTG) dosing requirements in the initial days of life.
  • To evaluate the impact of maternal DTG dosing history on neonatal DTG pharmacokinetics.
  • To inform the design of future clinical studies involving DTG in neonates.

Main Methods:

  • Population pharmacokinetic (PK) modeling and simulation were employed.
  • DTG PK data were gathered from pregnant women and infants in the IMPAACT P1026S study.
  • Monte Carlo simulations were used to predict neonatal DTG concentrations based on maternal DTG exposure status.

Main Results:

  • For infants not exposed to DTG prenatally, a 5 mg dose at birth followed by a dose after 48 hours maintained therapeutic concentrations.
  • For infants exposed to DTG prenatally, a 5 mg dose at 24 hours post-birth followed by a dose after 48 hours achieved target concentrations.
  • Neonatal DTG concentrations remained within the target range regardless of the timing of the last maternal DTG dose (6-24 hours prior to delivery).

Conclusions:

  • Neonatal dolutegravir (DTG) dosing needs to be individualized based on maternal DTG exposure history.
  • Proposed neonatal dosing regimens aim to optimize DTG exposure in the critical early days of life.
  • Findings provide a foundation for future clinical trials investigating DTG use in the neonatal population.